SHANGHAI, July 1 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that it had received an award from BASF for excellent service and outstanding contributions in the area of custom synthesis for new crop-protection active ingredients.
"We had been looking for a good CRO collaboration partner for years, and today I think we have found one, a top-notch partner," Dr. Alfred Hackenberger, President of the Specialty Chemicals Research Division at BASF, commented at the award ceremony. "And I know that WuXi will continue to provide the same excellent service in the future."
"We are pleased to receive this award by BASF in recognition of the efforts of WuXi's talented team," commented Dr. Ge Li, Chairman and CEO of WuXi AppTec. "We will continue to focus on customer service to earn the trust and support of our partners."
WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, we provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners to improve the success of research and shorten the time of development cost effectively in discovering and developing drugs and medical devices.
For more information, please contact: Ronald Aldridge Director of Investor Relations WuXi PharmaTech (Cayman) Inc. Tel: +1-201-585-2048 Email: Ron_Aldridge@wuxiapptec.com Web:http://www.wuxiapptec.com
|SOURCE WuXi PharmaTech (Cayman) Inc.|
Copyright©2009 PR Newswire.
All rights reserved